Dr. Carlos A. Jimenez, MD

Dr. Jimenez practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Jimenez's NPI, 1336247204, was assigned on September 21, 2006. Dr. Jimenez graduated from National University of Colombia in 1987. Dr. Jimenez holds Texas license L0832.

Dr. Jimenez's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Jimenez's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Jimenez practices. Vendor and product names are available with a free account.

Pulmonary disease is Dr. Jimenez's primary specialty in the NPI Registry, under taxonomy code 207RP1001X. Dr. Jimenez is board certified in critical care medicine by the American Board of Internal Medicine. Dmand AI has Dr. Jimenez's licenses on file in 2 states: Texas and Oklahoma.

Dmand AI lists asthma, chronic obstructive pulmonary disease (COPD), chronic sinusitis and pleural effusion among the conditions Dr. Jimenez treats.

CMS data shows 1,460 Medicare services from Dr. Jimenez across 19 procedure codes in 2024, for 545 Medicare patients. Medicare paid $61,189 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 545 Medicare patients who saw Dr. Jimenez in 2024. The largest group is 65 to 74, with 296 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 6% are also on Medicaid. Their average risk score is 2.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Jimenez's median patient age at 70, with 56% women.

In 2024, Dr. Jimenez wrote 39 Medicare Part D claims for 16 patients. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $5,075 in total drug cost. In 2018, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Jimenez for performance year 2024, reported as part of a group. Dr. Jimenez accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 126 papers to Dr. Jimenez, published from 2006 to 2025. 2018 was the busiest year, with 8. The most frequent topics are Lung Neoplasms, Bronchoscopy and Tomography, X-Ray Computed. Dr. Jimenez has published most often in Chest. Dr. Jimenez's most frequent co-authors are Rodolfo C. Morice, MD, David Edward Ost, MD and Roberto Fernando Casal, MD.

Dmand AI links Dr. Jimenez to 5 clinical trials. 1 is still active or recruiting. Conditions studied include Angina, Unstable, Burns and Leukemia, Myelogenous, Chronic, BCR-ABL Positive. M.D. Anderson Cancer Center sponsors the most, 3. Open Payments lists research payments to Dr. Jimenez that name 1 trial.

CMS Open Payments shows 6 general payments to Dr. Jimenez from 5 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 100% of the total. Pinnacle Biologics, Inc paid the most, $202. It also lists 2 research payments totaling $9,719 from 2016 to 2018, naming 1 clinical trial.

Dr. Jimenez graduated from National University of Colombia in 1987.

Dr. Jimenez is in network with 16 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. HMO plans come from the most carriers, 10. Check the plan with the practice before a visit.